Kimberly Hawkins serves as the Program Director at Genesis BioCapital, where she plays a pivotal role in shaping the company’s strategic direction for new program development. With a robust background in translational science and medicine, Kimberly is dedicated to bridging the gap between laboratory research...
Kimberly Hawkins serves as the Program Director at Genesis BioCapital, where she plays a pivotal role in shaping the company’s strategic direction for new program development. With a robust background in translational science and medicine, Kimberly is dedicated to bridging the gap between laboratory research and clinical application. Her expertise in clinical pharmacology and biomarkers is instrumental in designing and executing scientifically rigorous preclinical and clinical studies that propel drug and biomarker development programs forward.
At Genesis BioCapital, Kimberly leads key projects that focus on innovative approaches to neurodegenerative diseases, leveraging her skills in biochemistry and advanced techniques such as next-generation sequencing (NGS) and confocal microscopy. Her ability to synthesize complex scientific data into compelling presentations ensures that stakeholders are well-informed and engaged in the development process. Kimberly’s commitment to continuous learning not only enhances her own expertise but also fosters a culture of growth and development within her team.
In addition to her technical skills, Kimberly excels in people management and development, recognizing that a collaborative and motivated team is essential for success in the fast-paced biopharmaceutical industry. Her strategic vision and hands-on approach to experimentation enable her to navigate the complexities of supply strategy, ensuring that projects are executed efficiently and effectively. As she continues to drive innovation at Genesis BioCapital, Kimberly remains focused on her personal and professional goals, striving to make a meaningful impact in the field of drug development and patient care.
